FrancophonIA/ELRC3.0 huggingface dataset:
English: It is especially important that you tell your doctor if you are also taking: - Aminoglycosides (medicines used to treat severe infections), calcitonin (a type of medicine used to treat post-menopausal osteoporosis and hypercalcaemia), loop diuretics (a type of medicine to treat high blood pressure or oedema) or other calcium-lowering medicines, since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low.
Croatian: Osobito je važno da obavijestite liječnika ako uzimate: - Aminoglikozide (lijekovi za liječenje teških infekcija), kalcitonin (vrsta lijeka za liječenje post menopauzalne osteoporoze i hiperkalcemije), diuretici Henleove petlje (vrsta lijekova za liječenje visokog krvnog tlaka ili edema) ili drugi lijekovi koji snizuju razinu kalcija, budući da kombinacija ovih lijekova s bisfosfonatima može dovesti do preniskih razina kalcija u krvi.
English: Animal reproduction studies with zoledronic acid have shown reproductive toxicity (see section 5.3).
Croatian: Ispitivanja reprodukcije sa zoledronatnom kiselinom na životinjama pokazala su reproduktivnu toksičnost (vidjeti dio 5.3).
English: Zoledronic Acid Teva is supplied as packs containing 1, 4 or 10 vials.
Croatian: Zoledronatna kiselina Teva isporučuje se u pakiranjima od 1, 4 ili 10 bočica.
English: From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney.
Croatian: Iz koštanog tkiva se otpušta vrlo sporo natrag u sistemski krvotok i eliminira putem bubrega.
English: If you have pre-existing hypocalcaemia, it must be corrected before initiating the first dose of Zoledronic acid Teva.
Croatian: Ako već imate hipokalcemiju, ona se mora korigirati prije uvođenja prve doze Zoledronatne kiseline Teva.
English: How to store Zoledronic Acid Teva Contents of the pack and other information
Croatian: Kako čuvati Zoledronatnu kiselinu Teva Sadržaj pakiranja i druge informacije
English: The active substance in this medicine is zoledronic acid, which belongs to a group of substances called bisphosphonates.
Croatian: Djelatna tvar u ovom lijeku je zoledronatna kiselina, koja pripada skupini tvari koje se zovu bisfosfonati.
English: - Cancer, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking.
Croatian: - Rak, komorbiditetna stanja (npr. anemija, koagulopatije, infekcija), pušenje .
English: Table 2: Efficacy results (prostate cancer patients receiving hormonal therapy)
Croatian: Tablica 2: Rezultati djelotvornosti (bolesnici s karcinomom prostate koji primaju hormonsku terapiju)
English: − Osteonecrosis has also very rarely been seen occurring with other bones than the jaw, especially the hip or thigh.
Croatian: - Uočeno je da se osteonekroza također vrlo rijetko pojavila i na drugim kostima osim čeljusti, naročito na kuku ili bedrima.
English: - Other medicines that also contain zoledronic acid and which are used to treat osteoporosis and other non-cancer diseases of the bone, or any other bisphosphonate, since the combined effects of these medicines taken together with Zoledronic Acid Teva are unknown.
Croatian: - Druge lijekove koji također sadrže zoledronatnu kiselinu i koriste se za liječenje osteoporoze i drugih bolesti kostiju koje nisu uzrokovane rakom ili bilo koji drugi bisfosfonat, budući da kombinirani učinci ovih lijekova kad se uzimaju zajedno sa Zoledronatnom kiselinom Teva nisu poznati.
English: Very rare (may affect up to 1 in 10,000 people): - Fainting due to low blood pressure.
Croatian: Vrlo rijetko (mogu se javiti u do 1 na 10 000 osoba): - Nesvjestica zbog niskog krvnog tlaka.
English: - Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with zoledronic acid.
Croatian: - Ispitivanja infuzijskih linija napravljenih od polivinilklorida, polietilena i polipropilena pokazala su da nema inkompatibilnosti sa zoledronatnom kiselinom.
English: Zoledronic Acid Teva should not be used during pregnancy.
Croatian: Zoledronatna kiselina Teva ne smije se primjenjivati tijekom trudnoće.
English: - Difficulty in breathing with wheezing or coughing.
Croatian: - Otežano disanje uz piskanje u plućima ili kašljanje.
English: - Severe bone, joint and/or muscle pain, occasionally incapacitating.
Croatian: - Jaka bol u kostima, zglobovima i/ili mišićima, koja povremeno onesposobljuje.
English: What Zoledronic Acid Teva is and what it is used for
Croatian: Što je Zoledronatna kiselina Teva i za što se koristi
English: Do not use this medicine if you notice any particles or discoloration in the solution.
Croatian: Ovaj lijek se ne smije upotrijebiti ako primjetite bilo kakve čestice ili promjenu boje otopine.
English: - Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
Croatian: - Antiangiogene lijekove (primjenjuju se za liječenje raka), budući da je kombinacija ovih lijekova sa zoledronatnom kiselinom povezana sa povećanim rizikom od osteonekroze čeljusti.
English: The following conventional classification is used: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Croatian: Za to se koristila sljedeća uobičajena klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
English: Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of Zoledronic Acid Teva along with driving and operating of machinery.
Croatian: Nuspojave poput omaglice i somnolencije mogu utjecati na sposobnost upravljanja vozilima i rada sa strojevima te je stoga potreban oprez kad se tijekom primanja Zoledronatne kiseline Teva upravlja vozilima i radi sa strojevima.
English: - If you are being treated to reduce the amount of calcium in your blood, you will normally only be given a single infusion of Zoledronic Acid Teva.
Croatian: Ako se liječite radi snižavanja količine kalcija u krvi, obično ćete dobiti samo jednu infuziju
English: The recommended dose in hypercalcaemia (albumin-corrected serum calcium ≥ 12.0 mg/dl or 3.0 mmol/l) is a single dose of 4 mg zoledronic acid.
Croatian: Preporučena doza kod hiperkalcemije (serumski kalcij korigiran za albumin ≥ 12,0 mg/dl ili 3,0 mmol/l) je jednokratna doza od 4 mg zoledronatne kiseline.
English: Each plastic or clear glass vial contains 5 ml of a clear, colourless concentrate.
Croatian: Jedna plastična ili prozirna staklena bočica sadrži 5 ml bistrog, bezbojnog koncentrata.
English: Following initiation of therapy, serum creatinine should be measured prior to each dose of Zoledronic Acid Teva and treatment should be withheld if renal function has deteriorated.
Croatian: Nakon početka liječenja kreatinin u serumu treba mjeriti prije primjene svake doze Zoledronatne kiseline Teva, a liječenje treba obustaviti ako se funkcija bubrega pogorša.
English: How often Zoledronic Acid Teva is given - If you are being treated for the prevention of bone complications due to bone metastases, you will be given one infusion of Zoledronic Acid Teva every three to four weeks.
Croatian: Koliko se često daje Zoledronatna kiselina Teva - Ako se liječite radi sprječavanja koštanih komplikacija izazvanih metastazama, dobivat ćete jednu infuziju Zoledronatne kiseline Teva svaka tri do četiri tjedna.
English: The other ingredients are: mannitol, sodium citrate and water for injections.
Croatian: - Drugi sastojci su: manitol, natrijev citrat i voda za injekcije.
English: The European Medicines Agency has waived the obligation to submit the results of studies with the reference product containing zoledronic acid in all subsets of the paediatric population in the treatment of tumour-induced hypercalcaemia and prevention of skeletal-related events in patients with advanced malignancies involving bone (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja referentnog lijeka koji sadrži zoledronatnu kiselinu u svim podskupinama pedijatrijske populacije u liječenju hiperkalcemije izazvane tumorom i sprječavanju koštanih događaja u bolesnika s uznapredovalom zloćudnom bolešću koja zahvaća kosti (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Based on the review of both clinical trial and post-marketing cases, there is sufficient evidence to support an association between Zoledronic Acid Teva therapy, the reported event of hypocalcaemia, and the secondary development of cardiac arrhythmia.
Croatian: Na osnovi pregleda i kliničkih ispitivanja i post-marketinškog praćenja, postoje dostatni dokazi koji podupiru postojanje veze između liječenja Zoledronatnom kiselinom Teva, prijavljenih slučajeva hipokalcemije i sekundarnog razvoja srčanih aritmija.
English: 1Adverse events occurring with frequencies < 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of zoledronic acid (see section 4.8).
Croatian: 1 Štetni događaji koji nastaju s učestalošću < 5% bili su medicinski procijenjeni i pokazalo se da su u skladu s dobro utvrđenim sigurnosnim profilom zoledronatne kiseline (vidjeti dio 4.8).
English: Aseptic techniques must be followed during the preparation of the infusion.
Croatian: Tijekom pripreme infuzije morate se pridržavati aseptičkih tehnika.
English: - Sudden coldness with fainting, limpness or collapse.
Croatian: - Iznenadan osjećaj hladnoće povezan s nesvjesticom, hramanjem ili kolapsom.
English: What Zoledronic Acid Teva looks like and contents of the pack Zoledronic Acid Teva is supplied as a concentrate for solution for infusion.
Croatian: Kako Zoledronatna kiselina Teva izgleda i sadržaj pakiranja Zoledronatna kiselina Teva isporučuje se kao koncentrat za otopinu za infuziju.
English: During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.
Croatian: Bolesnicima treba savjetovati da tijekom liječenja bisfosfonatima prijave svaki bol u bedru, kuku ili preponama, i svakog bolesnika s takvim simptomima treba pregledati na nepotpuni prijelom bedrene kosti.
English: - if you have or have had pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth.
Croatian: - ako osjećate ili ste osjećali bol, oticanje ili utrnulost čeljusti, težinu u čeljusti ili klimanje zuba.
English: Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with Zoledronic Acid Teva.
Croatian: Smanjena razina kalcija u krvi (hipokalcemija), koja ponekad dovodi do mišićnih grčeva, suhe kože, osjećaja pečenja, zabilježena je u bolesnika liječenih Zoledronatnom kiselinom Teva.
English: In multiple myeloma patients, the risk of renal dysfunction may be increased when Zoledronic Acid Teva is used in combination with thalidomide.
Croatian: U bolesnika s multiplim mijelomom, rizik od poremećaja funkcije bubrega može biti povećan kad se primjenjuje Zoledronatna kiselina Teva u kombinaciji s talidomidom.
English: * Includes vertebral and non-vertebral fractures ** Accounts for all skeletal events, the total number as well as time to each event during the trial NR Not Reached
Croatian: ** Odnosi se na sve koštane događaje, njihov ukupni broj i vrijeme do svakog pojedinog događaja tijekom ispitivanja.
English: Other medicinal products containing zoledronic acid as active substances are available for osteoporosis indications and treatment of Paget´s disease of the bone.
Croatian: Dostupni su drugi lijekovi koji sadrže zoledronatnu kiselinu kao djelatnu tvar indicirani kod osteoporoze i za liječenje Pagetove bolesti kostiju.
English: Hypocalcaemia is an important identified risk with Zoledronic Acid Teva in the approved indications.
Croatian: Hipokalcemija je važan rizik prepoznat pri primjeni Zoledronatne kiseline Teva za odobrene indikacije.
English: The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:
Croatian: Sljedeće nuspojave navedene u tablici 1 prikupljene su iz kliničkih ispitivanja i prijava nakon stavljanja lijeka u promet, uglavnom kod kroničnog liječenja s 4 mg zoledronatne kiseline:
English: What you need to know before you are given Zoledronic Acid Teva
Croatian: Što morate znati prije nego primite Zoledronatnu kiselinu Teva
English: - Since no data are available on the compatibility of zoledronic acid with other intravenously administered substances, zoledronic acid must not be mixed with other medicinal products/substances and should always be given through a separate infusion line.
Croatian: - Budući da nema dostupnih podataka o kompatibilnosti zoledronatne kiseline s drugim tvarima za intravensku primjenu, zoledronatna kiselina ne smije se miješati s drugim lijekovima/tvarima i uvijek se mora primjenjivati kroz zasebnu infuzijsku liniju
English: In view of the potential impact of zoledronic acid on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine ≥ 400 μmol/l or ≥ 4.5 mg/dl for patients with TIH and ≥ 265 μmol/l or ≥ 3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance < 30 ml/min), the use of Zoledronic Acid Teva is not recommended in patients with severe renal impairment.
Croatian: S obzirom na mogući utjecaj zoledronatne kiseline na funkciju bubrega, nedostatak kliničkih podataka o sigurnosti primjene u bolesnika s teškim oštećenjem funkcije bubrega (u kliničkim ispitivanjima definiranim kao kreatinin u serumu ≥ 400 μmol/l ili ≥ 4,5 mg/dl u bolesnika s hiperkalcemijom izazvanom tumorom, odnosno ≥ 265 μmol/l ili ≥ 3,0 mg/dl u bolesnika s rakom i metastazama u kostima) na početku liječenja i ograničene farmakokinetičke podatke u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min) na početku liječenja, ne preporučuje se primjena Zoledronatne kiseline Teva u bolesnika s teškim oštećenjem funkcije bubrega.
English: An extension study was conducted in order to examine the long-term general and renal safety of once yearly or twice yearly zoledronic acid over the 12-month extension treatment period in children who had completed one year of treatment with either zoledronic acid or pamidronate in the core study.
Croatian: Produžetak ispitivanja proveo se da bi se ispitala dugotrajna opća sigurnost zoledronatne kiseline i njezina sigurnost za bubrege kod primjene jedanput ili dvaput godišnje tijekom 12-mjesečnog produžetka terapijskog razdoblja u djece koja su dovršila godinu dana liječenja zoledronatnom kiselinom ili pamidronatom u osnovnom ispitivanju.
English: Zoledronic Acid Teva is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min.
Croatian: Zoledronatna kiselina Teva ne preporučuje se u bolesnika koji prije početka liječenja imaju teško oštećenje funkcije bubrega, koje se u ove populacije definira kao klirens kreatinina manji od 30 ml/min.
English: - Weight increase.
Croatian: - Povećanje tjelesne težine.
English: Each vial contains 5 ml of concentrate.
Croatian: Jedna bočica sadrži 5 ml koncentrata.
English: The effects of intravenous zoledronic acid in the treatment of paediatric patients (age 1 to 17 years) with severe osteogenesis imperfecta (types I, III and IV) were compared to intravenous pamidronate in one international, multicentre, randomised, open-label study with 74 and 76 patients in each treatment group, respectively.
Croatian: Učinci intravenski primijenjene zoledronatne kiseline u liječenju pedijatrijskih bolesnika (u dobi od 1 do 17 godina) s teškim oblikom osteogenesis imperfecta (tipovi I, III i IV) uspoređeni su s učincima intravenski primijenjenog pamidronata u jednom međunarodnom, multicentričnom, randomiziranom ispitivanju otvorenog tipa na 74 odnosno 76 bolesnika u navedenim terapijskim skupinama.
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2°C - 8°C .
Croatian: Ako se ne primijeni odmah, korisnik je odgovoran za vrijeme i uvjete čuvanja, koji ne smiju biti dulji od 24 sata na temperaturi od 2°C - 8°C.
English: Cyclic Olefin Polymer (COP) plastic vial or clear glass vial (type I) with chlorobutyl/butyl flurotec stopper and aluminium cap with plastic flip-off cap.
Croatian: Plastična bočica od cikloolefinskog polimera ili bočica od prozirnog stakla (tipa I) s klorobutil/butil flurotec čepom i aluminijskim zatvaračem s plastičnom „flip-off“ kapicom.
English: In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30-60 ml/min, the following Zoledronic Acid Teva dose is recommended (see also section 4.4):
Croatian: U bolesnika s metastazama u kostima koji prije početka liječenja imaju blago do umjereno oštećenje funkcije bubrega, koje se u ove populacije definira kao klirens kreatinina od 30 do 60 ml/min, preporučuje se sljedeća doza Zoledronatne kiseline Teva (vidjeti također dio 4.4):
English: Table 1 Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Croatian: Nuspojave su navedene prema učestalosti prema sljedećoj konvenciji, s time da su prvo navedene najčešće nuspojave: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
English: Studies with glass bottles, as well as several types of infusion bags and infusion lines made from polyvinylchloride, polyethylene and polypropylene (prefilled with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% w/v glucose solution), showed no incompatibility.
Croatian: Ispitivanja sa staklenim bocama, kao i nekoliko vrsta infuzijskih vrećica i infuzijskih linija napravljenih od polivinilklorida, polietilena i polipropilena (napunjenih otopinom za injekciju natrijevog klorida od 9 mg/ml (0,9%) ili 5% m/V otopinom glukoze) nisu pokazala da postoji ikakva inkompatibilnost.
English: To assess the effects of 4 mg zoledronic acid versus pamidronate 90 mg, the results of two pivotal multicentre studies in patients with TIH were combined in a pre-planned analysis.
Croatian: Da bi se procijenili učinci 4 mg zoledronatne kiseline u usporedbi s 90 mg pamidronata, u unaprijed planiranoj analizi kombinirali su se rezultati dva ključna multicentrična ispitivanja u bolesnika s hiperkalcemijom izazvanom tumorom.
English: Hypersensitivity reaction
Croatian: - Reakcije preosjetljivosti.
English: Fracture adverse events of long bones in the lower extremities were reported in approximately 24% (femur) and 14% (tibia) of zoledronic acid-treated patients vs 12% and 5% of pamidronate-treated patients with severe osteogenesis imperfecta, regardless of disease type and causality but overall incidence of fractures was comparable for the zoledronic acid and pamidronate-treated patients: 43% (32/74) vs 41% (31/76).
Croatian: Nuspojava prijeloma dugih kostiju donjih ekstremiteta bila je zabilježena u približno 24% (bedrena kost) i 14% (goljenična kost) bolesnika liječenih zoledronatnom kiselinom naspram 12% odnosno 5% u bolesnika s teškim oblikom osteogenesis imperfecta liječenih pamidronatom, bez obzira na tip bolesti i uzrok, no ukupna incidencija prijeloma bila je slična u bolesnika liječenih zoledronatnom kiselinom i onih liječenih pamidronatom: 43% (32/74) naspram 41% (31/76).
English: Caution is advised when Zoledronic Acid Teva is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5).
Croatian: Savjetuje se oprez kod primjene Zoledronatne kiseline Teva s lijekovima za koje je poznato da uzrokuju hipokalcemiju budući da mogu imati sinergistički učinak s posljedičnom teškom hipokalcemijom (vidjeti dio 4.5).
English: Median time to relapse (re-increase of albumin-corrected serum calcium ≥ 2.9 mmol/l) was 30 to 40 days for patients treated with zoledronic acid versus 17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid).
Croatian: Medijan vremena do relapsa (ponovnog povišenja kalcija u serumu korigiranog za albumin ≥ 2,9 mmol/l) iznosio je 30 do 40 dana u bolesnika liječenih zoledronatnom kiselinom naspram 17 dana u onih liječenih pamidronatom u dozi od 90 mg (p-vrijednosti: 0,001 za 4 mg i 0,007 za 8 mg zoledronatne kiseline).
English: - Urticaria.
Croatian: - Koprivnjača.
English: Additionally, there have been sporadic reports of osteonecrosis of other sites, including the hip and femur, reported predominantly in adult cancer patients treated with zoledronic acid.
Croatian: Dodatno, bilo je sporadičnih prijava osteonekroze drugih anatomskih mjesta, uključujući kuk i bedrenu kost, koje su bile prijavljene pretežno u odraslih bolesnika oboljelih od raka liječenih
English: Uncommon (may affect up to 1 in 100 people): - Pain in the mouth, teeth and/or jaw, swelling or non-healing sores inside the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth.
Croatian: Manje često (mogu se javiti u do 1 na 100 osoba): - Bol u ustima, zubima i/ili čeljusti, oteklina ili ranice u ustima ili čeljusti koje ne cijele, iscjedak, utrnulost ili osjećaj težine u čeljusti, klimanje zuba.
English: - Conjunctivitis.
Croatian: - Konjunktivitis.
English: The safety margins relative to renal effects were narrow in the long-term repeat-dose parenteral animal studies but the cumulative no adverse event levels (NOAELs) in the single dose (1.6 mg/kg) and multiple dose studies of up to one month (0.06-0.6 mg/kg/day) did not indicate renal effects at doses equivalent to or exceeding the highest intended human therapeutic dose.
Croatian: Dugotrajna ispitivanja ponovljene parenteralne doze u životinja pokazala su uzak raspon sigurnosti s obzirom na učinke na bubrege, ali najviša kumulativna razina koja ne uzrokuje štetni događaj (NOAEL) u ispitivanjima jednostruke doze (1,6 mg/kg) i višestrukih doza u trajanju do jednog mjeseca (0,06 - 0,6 mg/kg na dan) nije imala učinke na bubrege pri dozama jednakima ili višima od najviše terapijske doze namijenjene ljudima.
English: For storage condition after dilution of the medicinal product, see section 6.3.
Croatian: Uvjete čuvanja nakon razrjeđivanja lijeka vidjeti u dijelu 6.3.
English: After dilution, it is preferable to use the diluted medicine immediately.
Croatian: Nakon razrjeđivanja, preporučuje se razrijeđeni lijek odmah primijeniti.
English: There was faster normalisation of corrected serum calcium at day 4 for 8 mg zoledronic acid and at day 7 for 4 mg and 8 mg zoledronic acid.
Croatian: Ustanovljena je brža normalizacija korigiranog kalcija u serumu 4. dana kod doze zoledronatne kiseline od 8 mg i 7. dana kod doze zoledronatne kiseline od 4 mg i 8 mg.
English: - From a microbiological point of view, the diluted solution for infusion should be used immediately.
Croatian: - S mikrobiološkog stajališta, razrijeđena otopina za infuziju treba se odmah primijeniti.